Asterias Biotherapeutics, Inc. (NYSE: AST) today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Asterias Biotherapeutics (AST) Reports Exclusive License Agreement with Regents of University of California; Begins Second Pre-Clinical Collaboration Initiated to Test Efficacy of AST-OPC1July 12, 2018 7:12 AM Asterias Biotherapeutics (AST) Set to Open Higher by 50% Following Positive Outcome from Safety Review Committee for AST-VAC2July 11, 2018 7:26 AM Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)July 11, 2018 7:00 AM